Source link : https://www.newshealth.biz/health-news/fda-greenlights-imaging-agent-to-detect-residual-cancer-after-lumpectomy/
The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the Lumicell Direct Visualization System (DVS) or another fluorescence imaging device approved for use with pegulicianine. The fluorescent dye is administered intravenously before surgery. Then after the tumor is removed, […]
Author : News Health
Publish date : 2024-04-18 17:02:40
Copyright for syndicated content belongs to the linked Source.